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BRIEF CLINICAL REPORTSExplantation of a 44-year-old Starr–Edwards mitral valve for
delayed hemolysisJoss Fernandez, MD, and Robert Saeid Farivar, MD, PhD, Iowa City, IowaFIGURE 1. Starr–Edwards 44-year-old explanted mitral valve, model
6120, with sewing ring removed. Valve is intact, with yellowing of ball.CLINICAL SUMMARY
A 68-year-old woman was admitted 44 years after undergo-
ing mitral valve replacement with a Starr–Edwards (SE)
prosthesis (Edwards Lifesciences, Irvine, Calif) for rheu-
matic mitral valve stenosis. Since implantation of the pros-
thesis in 1965 via thoracotomy, the patient had done well
and maintained her anticoagulation with warfarin sodium
(Coumadin). She now had fatigue and anemia. Of note,
2 years earlier the patient had had third-degree heart block
necessitating the implantation of a dual-chamber pacemaker.
A full workup including upper and lower endoscopy did not
reveal a source of bleeding. Hematologic testing showed
decreased haptoglobin, a high lactic dehydrogenase value,
and increased reticulocyte count, consistent with a hemolytic
anemia. Bone marrow biopsy was performed, which showed
erythroid hyperplasia, normocellular bone marrow, normal
megakaryocytes, and absent iron, indicative of iron defi-
ciency anemia. Despite iron replacement therapy she contin-
ued to become increasingly transfusion dependent. She
received 9 units of blood in 1 month alone. Echocardiogram
revealed normal prosthetic mitral valve function with a mitral
valve mean gradient of 6 mm Hg, a severely calcified aortic
valve with an aortic valve mean gradient of 58 mm Hg, and
an aortic valve area of less than 1.0 cm2.
Aortic and mitral valve replacements were performed
with bioprosthetic valves. Reoperative median sternotomy
was performed. After standard cannulation, Sondergaard’s
groove was used to expose the mitral valve. The SE valve
was in good condition without paravalvar leak. The mitral
valve was explanted. The SE ball and cage were undamaged
(Figure 1). There was no evidence of cloth tears or pannus
overgrowth. The color of the ball had changed, presumably
from lipid infiltration, but the ball was otherwise without pit-
ting or defects. The patient underwent successful aortic
valve replacement with a 21-mm Edwards Magna Thermafix
bovine pericardial valve (Edwards) and mitral valve replace-
ment with a 25-mm St Jude Epic porcine valve (St Jude
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strated resolution of her hemolytic anemia, with an increase
in hematocrit value from 29% to 38% without transfusion.
DISCUSSION
Native aortic valve stenosis alone has rarely been associated
with hemolysis,1 although gradients exceeding 50 mm Hg
have been shown to cause mechanical hemolysis.2 The turbu-
lence associated with the combination of a mechanical mitral
valve and aortic stenosis has previously been implicated as
a cause of hemolysis.3 We believe that this combination re-
sulted in hemolytic anemia in this patient, inasmuch as the on-
set of hemolysis coincided with worsening of aortic stenosis.
This resolved after aortic and mitral valve rereplacement.
Developed by engineer Miles Edwards and Dr Albert
Starr, the SE valve was first successfully implanted on
Sept 21, 1960. Since then, more than 250,000 patients
have received the valve. The model 6120 SE mitral valve
prosthesis used in this patient was introduced in 1965 with
cloth-covered sewing rings and bare-metal struts. This dra-
matically reduced the incidence of thromboembolism from
the previous generation of the valve, but wear of the valve
cloth caused hemolysis. In our patient, the ball was in
remarkably good condition; thus pitting was not a cause of
hemolysis. Late hemolysis has been previously reported
up to 25 years after mitral valve replacement. The duration
of survival to explantation is also remarkable. Others have
reported explantation of the SE aortic valve 33 years after
implantation4 and of the SE mitral prosthetic valve 31 years
after implantation.5 There is also a report of a 40-year sur-
vival of a patient with an SE valve in the mitral position.6rdiovascular Surgery c Volume 140, Number 3 e35
Brief Clinical ReportsThe current patient is, to our knowledge, the oldest reported
to undergo explantation of an SE valve, and the duration of
implantation is the longest reported. The case demonstrates
the efficacy and safety of double valve replacement for de-
layed hemolysis in a mechanical valve, even in patients in
whom the valve has been seated for more than 4 decades.
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Cutter and Starr–Edwards prostheses. Ann Thorac Surg. 2008;85:e14-6.Two cases of aneurysm of the anterior mitral valve leaflet associated
with transcatheter aortic valve endocarditis: A mere coincidence?Nicolo Piazza, MD, FRCPC,a Sebastanio Marra, MD,b John Webb, MD,c Maurizio D’Amico, MD,b
Mauro Rinaldi, MD,b Massimo Boffini, MD,d Chiara Comoglio, MD,d Paolo Scacciatella, MD,c
Arie-Pieter Kappetein, MD, PhD,e Peter de Jaegere, MD, PhD,a and Patrick W. Serruys, MD, PhD,a
Rotterdam, The Netherlands, Turin, Italy, and Vancouver, British Columbia, CanadaThe incidence of transcatheter aortic valve endocarditis
(TAVE) is currently unknown. To the best of our knowl-
edge, 2 clinical case reports of TAVE have been published
(1 Edwards SAPIEN [Edwards Lifesciences, Irvine, Calif]
and 1 Medtronic CoreValve ReValving System [Medtronic
CV, Luxembourg Sarl]).1,2 Interestingly, both cases were
associated with aneurysm and perforation of the anterior
mitral valve leaflet—a link that has not been previously re-
ported. We briefly review the clinical presentations of these
cases and discuss the possible implications of endocarditis in
the context of transcatheter aortic valve implantation.
CLINICAL SUMMARIES
Patient 1
CoreValve ReValving System (Figure 1, A and B).
Comoglio and associates1 reported a case of TAVE in
a 66-year-old man who underwent transfemoral aortic valveimplantation with the CoreValve ReValving System. The
prosthesis was positioned too low into the left ventricular
outflow tract, resulting in moderate paravalvular aortic regur-
gitation. After postimplant balloon dilatation, the aortic
regurgitation was reduced to a mild–moderate degree. The
postoperative course was complicated by ventricular
arrhythmias of unknown etiology. One month after the pro-
cedure, the patient was readmitted with heart failure and re-
current ventricular arrhythmias. Echocardiography revealed
moderate paravalvular aortic regurgitation, preserved left
ventricular function, but progressive left ventricular dilata-
tion. Three months after implantation, the patient had fever
and blood cultures positive for Corynebacterium. Transeso-
phageal echocardiography showed severe mitral regurgita-
tion resulting from a perforated aneurysm of the anterior
mitral valve leaflet at the level of the ventricular edge of
the metal frame. The patient underwent surgical aortic valve
replacement with a 23-mm Carpentier–Edwards biopros-
thetic valve (Edwards) and pericardial patch repair of the
anterior mitral valve leaflet. In addition to a vegetative lesion
observed on the transcatheter aortic valve cusp, the left main
coronary artery ostium was obstructed by a strut of the
CoreValve frame. The postoperative course was uneventful
and the patient was discharged on postoperative day 7.
Patient 2
Edwards SAPIEN prosthetic heart valve (Figure 1, C
and D). Wong and associates2 reported a case of TAVE in
an 88-year-old man who underwent transfemoral aortic
valve implantation with a 26-mm Edwards SAPIENery c September 2010
